Progression of Undifferentiated Arthritis to Inflammatory Arthritis https://t.co/Ozr8jPnAcx https://t.co/Jctal4xznB

• Progression of Undifferentiated Arthritis to Inflammatory Arthritis | RheumNow

EULAR/PReS Still's Disease Management Recommendations Since 2022, EULAR and the Paediatric Rheumatology European Society (PReS) have been working to establish clinical practice guidelines for the diagnostics and management of systemic juvenile idiopathic arthritis (sJIA) and… https://t.co/JZidoWEZSq https://t.co/miwnaw5BZ3

Pain Relief with JAK Inhibitors or Anti-TNFs ? Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest. https://t.co/oIgNxBF518 https://t.co/L9g9MJQbQx

• Pain Relief with JAK Inhibitors or Anti-TNFs ? | RheumNow

Adult (133,216) vs Pediatric (955) pts on JAKi - analysis of FAERS shows both @ incr risk for infections & GI AEs. Pediatric pts had more blood and lymphatic disorders, while adults had more CNS and MSK/CTD disorders https://t.co/SKjzANYPSq https://t.co/S6JPYuvSlf

• Analysis of publicly available adverse events reported for pediatric patients t…

Lupus nephritis & CKD considerations: - Non-immune factors: obesity, HTN, Na- or protein-diets, NIDDM, pregnancy, mephrotoxic meds, smoking can add to CKD - use inhibitors renin–angiotensin & SGLT2 inhibitor w/ proteinuria & low GFR https://t.co/IgL4hpixOm https://t.co/FvmLhf7tQq

• Lupus nephritis-related chronic kidney disease

NOR-Gout study shows Non-adherence to urate lowering therapy after 5 years is related to poor gout outcomes. 5-year Observational study of 163 patients showed overall good ULT adherence but nonadherent had more flares (33 vs 10%) & less at target (45 vs 87%)… https://t.co/wHQIRbIoBu https://t.co/eBKL4uRfZc

UCB & Biogen report positive topline results of Phase 3 RCT of Dapirolizumab Pegol (anti-CD40L) in #SLE & will launch a 2nd Ph 3 RCT in 2024. Phase 3 PHOENYCS GO study was 48 wks of DAP vs PBO in mod-severe SLE w/ BILAG improvement by wk 48 https://t.co/G1DJf31T6t https://t.co/DgpTObIXrB

• UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapiroli…

Genentech announced top line results of the REGENCY Phase III study of obinutuzumab (Gazyva) in lupus nephritis. 271 LN (class III or IV; +/- V) taking MMF & steroids were given placebo or OBIN for 76 wks. OBIN was superior @ complete renal resp at 76 wks… https://t.co/Um9du7fgxE https://t.co/RRWumnbTuy

NEJM Clinical Images: DLE - A 42-year-old woman presented with a 2-year history of a facial rash. A skin examination after removal of her makeup showed an indurated plaque, areas of hyperpigmentation and hypopigmentation, and scattered nodules. https://t.co/dcmLEwV359 https://t.co/XIjZblDSC3

• Discoid Lupus Erythematosus | NEJM

INVIGORATE-2 Study - IV Secukinumab in Active Psoriatic Arthritis The INVIGORATE-2 trial reports that intravenous (IV) secukinumab (SEC) is both effective and safe in patients with active psoriatic arthritis (PsA), demonstrating improvements on par with subcutaneous SEC.… https://t.co/I1TVGIHByN https://t.co/WwSRQxrKAE

Limited Efficacy of Muscle Relaxants for Chronic Pain A systematic review of long-term muscle relaxant use for chronic pain suggests they may be effective in treating trigeminal neuralgia, cramps, and neck pain, but not fibromyalgia, low back pain, and other pain syndromes.… https://t.co/sReBxhSpWH https://t.co/tQGWKPwokn